Shares of Apollomics Inc. (NASDAQ:APLM – Get Free Report) fell 1.6% on Thursday . The stock traded as low as $18.73 and last traded at $18.80. 1,802 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 16,077 shares. The stock had previously closed at $19.11.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Report on APLM
Apollomics Stock Down 1.6%
Hedge Funds Weigh In On Apollomics
A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC bought a new stake in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent quarter. 19.13% of the stock is currently owned by hedge funds and other institutional investors.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
Recommended Stories
- Five stocks we like better than Apollomics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
